Icatibant
Product description
is a synthetic peptidomimetic drug consisting of ten amino acids, and acts as an effective and specific antagonist of bradykinin B2 receptors. It has been approved in the EU for use in hereditary angioedema, and is under investigation for a number of other conditions in which bradykinin is thought to play a significant role. Icatibant currently has orphan drug status in the United States and FDA approved on August 25, 2011. HAE (hereditary angiodysplasia)
Read more
Specifications
CAS Registry Number | 130308-48-4 |
---|---|
Categories | BiopharmaceuticalsBiopharmaceuticals (general category); APIs (Active Pharmaceutical Ingredients)Peptides |
Sales markets | Western Europe; Eastern Europe; Asia; North America |
Supplied from | China |
More products from Chengdu Shengnuo Biopharm Co Ltd
Products from other suppliers
❮
❯
-
VALSARIN 80/VALSARIN 160/VALSARIN 320
-
NURONORM
-
DERMOGEL NEW to treat inflammatory skin conditions
-
Anlitin (Levonorgestrel 1.5 mg) Tablet
-
Levocarnitine (LEKARNITIN) 1 G/5 ML SOLUTION FOR I.V. INJECTION
-
FOOD GRADE EPOXY COATING FOR INTERNAL POTABLE TANK PIPELINE - CLEAN TECH PW
-
Synatura Syrup
-
Ectoin® Allergy Eye Drops 2% - The innovation for treatment and prevention of allergic conjunctivitis symptoms
-
Kalmosan Skin Lotion
-
ComBE Five Pentavalent DTP-HepB-Hib
Icatibant
Are you a supplier?
Here's what CPhI Online can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation